EUVIMEDScopri EUVIMED
KommentarOpen access · CC BY 4.0

Therapeutic potential of CDK11 in cancer

Dalibor Blazek iD

Clinical and Translational Medicine · 2023-03 · 13 (3)

DOI: 10.1002/ctm2.1201 ↗

At a glance

Kommentar in Clinical and Translational Medicine, published online on 2023-02-28. Written by Dalibor Blazek. Institution: Central European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic. Major MEDLINE topics: Cyclin-Dependent Kinases, Neoplasms. Cited 22 times so far (Crossref); 12 references. The full text is freely available (open access, CC BY 4.0). Funded by: the Czech Science Foundation.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Human cyclin‐dependent kinases (CDKs) direct the progression of the cell cycle and transcription. They are deregulated in tumours, and despite their involvement in the regulation of basic cellular processes, many CDKs are promising targets for cancer therapy. CDK11 is an essential gene for the growth of many malignancies; however, its primary cellular function has been obscure, and the mode‐of‐action of OTS964, the first CDK11 inhibitor and antiproliferative compound, has been unknown. A recent study has shown that OTS964 prevents spliceosome activation, revealing a key role of CDK11 in the regulation of pre‐mRNA splicing. In light of these findings, we discuss the therapeutic potential of CDK11 in cancer.

Subjects

MeSH terms (MEDLINE)

Cyclin-Dependent KinasesNeoplasmsHumansCell CycleCell DivisionRNA Splicing

Author keywords

CDK11OTS964SF3B1cancerpladienolide Bspliceosomesplicing

Substances

Cyclin-Dependent KinasesCDK19 protein, human

Authors and institutions

  • Central European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic.

ORCID profiles: Dalibor Blazek

Funding

  • the Czech Science Foundation

Cite

APA

Blazek, D. (2023). Therapeutic potential of CDK11 in cancer. Clinical and Translational Medicine, 13(3). https://doi.org/10.1002/ctm2.1201

Vancouver

Blazek D. Therapeutic potential of CDK11 in cancer. Clinical and Translational Medicine. 2023;13(3). doi:10.1002/ctm2.1201

BibTeX
@article{Blazek2023,
  author = {Blazek, Dalibor},
  title = {Therapeutic potential of CDK11 in cancer},
  journal = {Clinical and Translational Medicine},
  year = {2023},
  volume = {13},
  number = {3},
  doi = {10.1002/ctm2.1201}
}
Start for free →